Cash-flow borrowing shields corporate R&D from rate hikes
A 25-basis-point rate hike lowers long-term output by 0.12 percent because firms without cash-flow credit cut research outlays, according to a Bank of England working paper. Excluded firms absorb the largest productivity losses despite producing four times more breakthrough patents.
Diverging paths for corporate research
An empirical analysis linking Compustat balance sheets with DealScan syndicated loan records across 895 U.S. firms from 1997 to 2017 reveals that monetary policy shocks transmit unevenly to innovation.
Following an unanticipated 25-basis-point interest rate increase, operating cash flow declines uniformly across firms, but research and development spending diverges sharply.
Firms without access to cash flow-based borrowing—where credit limits are set against earnings rather than physical collateral—cut research outlays by 1.8 percentage points more in the first year than those with access.
On average, aggregate innovation spending drops by 1.0 percent, reaching its trough between seven and nine quarters after the shock.
The cost of excluded innovators
In a New Keynesian endogenous growth model, a 25-basis-point tightening creates a persistent output loss of 0.12 percent of trend.
Extending cash-flow borrowing to all firms reduces this aggregate loss by 30 percent.
However, the burden falls heavily on non-borrowers, whose productivity shortfall is nearly double that of borrowers.
Patent records show these excluded firms generate 17.15 patents per year compared to 5.83 for borrowers, and produce more than four times as many breakthrough patents.
Misallocated pain and lasting damage
Central banks consistently underestimate how rate hikes harm supply by punishing high-quality innovators.
Blanket subsidies fail because financing constraints hit younger, research-intensive firms hardest.
Tightening leaves lasting structural scars unless authorities provide targeted credit buffers.